Advertisement
HCM vs TAK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a Buy and TAK is a Buy.
HCM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HCM turned positive on November 06, 2026. Looking at past instances where HCM's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HCM as a result. In 65 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
HCM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HCM crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
The 50-day moving average for HCM moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCM advanced for three days, in 196 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
HCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 136 of 180 cases where HCM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. HCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.090) is normal, around the industry mean (6.379). HCM has a moderately high P/E Ratio (151.600) as compared to the industry average of (0.548). Projected Growth (PEG Ratio) (4.030) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.268) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Aroon Indicator for TAK shows an upward move is likely
TAK's Aroon Indicator triggered a bullish signal on November 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 283 similar instances where the Aroon Indicator showed a similar pattern. In 157 of the 283 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 46 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 48%.
The Moving Average Convergence Divergence (MACD) for TAK just turned positive on October 14, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in 20 of 43 cases over the following month. The odds of a continued upward trend are 47%.
TAK moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 157 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.009) is normal, around the industry mean (6.379). P/E Ratio (-0.402) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.202). Dividend Yield (0.056) settles around the average of (0.062) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
HCM | TAK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 15 | |
SMR RATING 1..100 | 81 | 91 | |
PRICE GROWTH RATING 1..100 | 42 | 37 | |
P/E GROWTH RATING 1..100 | 1 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for HCM (95). This means that TAK’s stock grew significantly faster than HCM’s over the last 12 months.
TAK's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for HCM (100). This means that TAK’s stock grew significantly faster than HCM’s over the last 12 months.
HCM's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as TAK (91). This means that HCM’s stock grew similarly to TAK’s over the last 12 months.
TAK's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as HCM (42). This means that TAK’s stock grew similarly to HCM’s over the last 12 months.
HCM's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for TAK (97). This means that HCM’s stock grew significantly faster than TAK’s over the last 12 months.
| HCM | TAK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 45% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 46% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 48% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 47% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 48% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 49% |
| Advances ODDS (%) | 2 days ago 71% | 6 days ago 50% |
| Declines ODDS (%) | 14 days ago 78% | 8 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HCM’s FA Score shows that 1 FA rating(s) are green while TAK’s FA Score has 2 green FA rating(s).
- HCM’s FA Score: 1 green, 4 red.
- TAK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HCM’s TA Score shows that 8 TA indicator(s) are bullish while TAK’s TA Score has 5 bullish TA indicator(s).
- HCM’s TA Score: 8 bullish, 2 bearish.
- TAK’s TA Score: 5 bullish, 4 bearish.
Price Growth
HCM (@Pharmaceuticals: Generic) experienced а +15.45% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.54%. For the same industry, the average monthly price growth was -8.98%, and the average quarterly price growth was +7.99%.
Reported Earning Dates
HCM is expected to report earnings on Nov 13, 2026.
TAK is expected to report earnings on Jan 28, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.54% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
HCM and
Correlation & Price change
A.I.dvisor tells us that HCM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and ACET's prices will move in lockstep.
| Ticker / NAME | Correlation To HCM | 1D Price Change % | ||
|---|---|---|---|---|
| HCM | 100% | +1.06% | ||
| ACET - HCM | 29% Poorly correlated | -1.97% | ||
| CGC - HCM | 27% Poorly correlated | -4.41% | ||
| GELS - HCM | 25% Poorly correlated | +1.66% | ||
| SNDL - HCM | 25% Poorly correlated | -1.06% | ||
| TAK - HCM | 23% Poorly correlated | +0.33% | ||
More | ||||
TAK and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | +0.33% | ||
| HLN - TAK | 43% Loosely correlated | -1.86% | ||
| COLL - TAK | 29% Poorly correlated | +2.07% | ||
| ANIK - TAK | 28% Poorly correlated | +0.14% | ||
| ZTS - TAK | 28% Poorly correlated | +3.68% | ||
| PRGO - TAK | 27% Poorly correlated | +6.94% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| METW | 24.06 | 1.22 | +5.35% |
| Roundhill META WeeklyPay ETF | |||
| FRNW | 21.61 | 0.25 | +1.17% |
| Fidelity Clean Energy ETF (FRNW) | |||
| MCOW | 21.76 | N/A | N/A |
| Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) | |||
| IBTQ | 24.31 | -0.02 | -0.08% |
| iShares iBonds Dec 2035 Term Treasury ETF (IBTQ) | |||
| COMT | 35.26 | -0.70 | -1.95% |
| iShares U.S. ETF Trust iShares GSCI Commodity Dynamic Roll Strategy ETF (COMT) | |||